Analysis of adverse drug reactions in the treatment of rheumatological diseases with biological medicinal products – a systematic review of scientific publications
Vol. 27 No. 4 (2019), Original Articles
Vol. 27 No. 4 (2019)

Analysis of adverse drug reactions in the treatment of rheumatological diseases with biological medicinal products – a systematic review of scientific publications

Original Articles
https://doi.org/10.35465/27.4.2019.pp3-17
Published December 31, 2019
Iva Parvova
Clinic of Rheumatology, Department of Internal Medicine, Medical University – Sofia, Bulgaria
E. Hristov
Faculty of Chemistry and Pharmacy, Sofia University “Sv. Kliment Ohridski” – Sofia, Bulgaria
A. Rangelov
Faculty of Chemistry and Pharmacy, Sofia University “Sv. Kliment Ohridski” – Sofia, Bulgaria
PDF BG/EN

Keywords

biological medicinal products
adverse drug reactions
rheumatological diseases
scientific publications
systematic review

How to Cite

Parvova, I., Hristov, E., & Rangelov, A. (2019). Analysis of adverse drug reactions in the treatment of rheumatological diseases with biological medicinal products – a systematic review of scientific publications. Rheumatology (Bulgaria), 27(4), 3-17. https://doi.org/10.35465/27.4.2019.pp3-17
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

To analyze reports of adverse drug reactions (ADRs) occurring during and after treatment of rheumatologic diseases with biological medicinal products (BMPs), published in the scientific literature; to determine the type, frequency, grade of severity and evaluate the causality with the ongoing treatment. The literature search was conducted in MEDLINE and PubMed databases for the period from November 2002 to November 2016. We found 710 publications, and 225 papers were selected for data extraction. We carried out descriptive and variational analyses as basic statistical analyses. We defined mean values, standard deviation, minimum, maximum, 95% confidence intervals. We assessed the results using PICOS instrument – population, intervention, comparison, outcomes and study design. The analyzed population included 137,564 patients with rheumatic diseases. Original articles and reviews account for the largest share of publications - 183 (81.33%). The most frequently used medicinal products were monoclonal antibodies. We found data of 284 types of ADRs. The most commonly reported ADRs were: common infections, development (activation) of tuberculosis infection, malignancies. ADRs were found in 12,979 patients, i.е. in 9,43% of the population, there was at least one ADR. Our systematic review has shown increased interest in the pharmacovigilance of biological medicinal products. The larger share of scientific publications, however, use non-standardized terminology to describe ADRs, which is not in line with the current pharmacovigilance concept. Ignorance of the notions, inaccurate and incorrect handling of scientific-regulatory terminology, and errors in ADRs reporting and publication in scientific literature do not allow for systematic reviews in this field.
https://doi.org/10.35465/27.4.2019.pp3-17
PDF BG/EN

References

  1. European Medicines Agency. MabThera: EPAR – Medicine overview. First published: 30/10/2009. (Cited 2019 May 15). Available from: https://www.ema.europa.eu/en/medicines/ human/EPAR/mabthera
  2. Parvova I, Hristov E, Rashkov R, Getov I. Retrospective study of adverse drug reaction in Bulgarian population of patient with inflammatory joint diseases treated with biological medicinal products Revmatologiia (Bulgaria), 2016, 24 (1) pp. 17-18.
  3. Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries, Biologics, 2015, 9, 1-6.
  4. Harris, JD, Quatman, CE, Manring, MM et al. How to Write a Systematic Review. The American Journal of Sports Medicine, 2014,42(11), 2761-2768. https://doi. org/10.1177/0363546513497567
  5. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. 2013.
  6. Centre for reviews and dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York: University of York; 2006.
  7. Moher D, Liberati A, Tetzlaff J et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009,6(7): e1000097. doi:10.1371/ journal.pmed1000097
  8. Shamseer L, Moher D, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;350:g7647. doi: 10.1136/bmj.g7647.
  9. Hutton B, Salanti G, Caldwell DM et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. doi: 10.7326/M14-2385.
  10. Gossec L., Smolen J.S., Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis. 2015, Published online: 07 December 2015. doi:10.1136/annrheumdis-2015-208337
  11. Ramiro S., Gaujoux-Viala C., Nam J.L et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 2015,73, 529-535.
  12. Smolen J. S., Landewé R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis, 2017 Published online: 06 March 2017. doi:10.1136/ annrheumdis-2016-210715.
  13. Van der Heijde D., Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, et al. (2017)Update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Ann Rheum Dis, 76, 978-991.
  14. Methley AM, Campbell S, Chew-Graham C et al. PICO, PICOS and SPIDER: a comparison study of specifi city and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579. Published 2014 Nov 21. doi:10.1186/s12913-014-0579-0.
  15. MedDRA. System Organ Class of MedDRA version 12.0 (Cited 2019 June 30). Available from: https://www.meddra. org/how-to-use/support-documentation/english.
  16. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE version 4.03, June 14, 2010), (Cited 2019 June 30). Available from: https:/ / evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-4_ QuickReference_8.5x11.pdf.
  17. Lewin S, Glenton C, Oxman AD: Use of qualitative methods alongside randomised controlled trials of complex healthcare interventions: methodological study.BMJ 2009, 339(b3496).
  18. European Commission. Pharmacovigilance. [Cited 2019 May 15]. Available from: http://ec.europa.eu/health/humanuse/ pharmacovigilance/index_en.htm.
  19. Directive 2001/83/EU of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. OJ Eur Union (Cited 2019 June 30). Available from: http://data. europa.eu/ eli/dir/2001/83/oj.
  20. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. OJ Eur Union (Cited 2019 June 30). Available from: http://data.europa.eu/ eli/reg/2004/726/oj.
  21. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance). OJ Eur Union 348, 31.12.2010, 74-99 (Cited 2019 June 30). Available from: https://eur-lex.europa.eu/eli/dir/2010/84/oj.
  22. European Medicines Agency. Humira: EPAR – Medicine overview. First published: 24/11/2009. (Cited 2019 May 15). Available from: https://www.ema.europa.eu/en/medicines/ human/EPAR/humira.
  23. European Medicines Agency. Enbrel : EPAR – Summary for the public. First published: 11/09/2009. (Cited 2019 May 15). Available from: https://www.ema.europa.eu/en/medicines/ human/EPAR/enbrel.
  24. European Medicines Agency. RoActemra: EPAR – Summary for the public. First published: 18/02/2009. (Cited 2019 May 15). Available from: https://www.ema.europa.eu/en/ medicines/human/EPAR/roactemra.
  25. European Medicines Agency. Cimzia: EPAR – Summary for the public. First published: 22/10/2009. (Cited 2019 May 15). Available from: https://www.ema.europa.eu/en/medicines/ human/EPAR/cimzia-0.
  26. European Medicines Agency. Simponi: EPAR – Summary for the public. First published: 20/10/2009. (Cited 2019 May 15). Available from: https://www.ema.europa.eu/en/medicines/ human/EPAR/simponi.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.